Clinical manifestations of ulcerative colitis and Crohn's disease
Keywords:
Ulcerative colitis, Crohn's disease, clinical manifestationsAbstract
Crohn's disease (CD) and ulcerative colitis (UC) are part of the group of inflammatory bowel diseases (IBD), which progressively or in the form of outbreaks affect the patient suffering from it. They are characterized by periods of activity and remission or quiescence and have unknown etiology. The most accepted theory is that they occur as a result of the interaction between the host and the environment, including the intestinal microbiota, the immune system, genetics and specific environmental factors. It is very important the adequate evaluation and the realization of the correct clinical history where all the present symptoms and the severity of them, will allow to classify the disease based on the different scales described and consequently according to severity, extension and presence or absence of complications to decide early on the therapeutic strategy that allows us to achieve remission.Downloads
References
Fernando Magro, Paolo Gionchetti, Rami Eliakim, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis.Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis, 2017, 649–670.
Fernando Gomollón, Axel Dignass, Vito Annese,et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn´s Diseases 2016: Part 1. Dianosis and Medical Management. Journal of Crohn's and Colitis, 2016, 1-23.
J.K. Yamamoto-Furusho, F. Bosques-Padilla, J. de-Paula, et al. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Organización Panamericana de Crohn y Colitis. Revista de Gastroenterología de México. 2017;82(1):46-84.
S. P. L. Travis, P. D. R. Higgins, T. Orchard, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 34: 113–124.
Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol 2005;3:11–24.
Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004;126:1518–32.
Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999;116:1464–86.
Hamzaoglu I, Hodin RA. Perianal problems in patients with ulcerative colitis. Inflamm Bowel Dis 2005;11:856–9.
Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2:1041-8.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical,molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A: 5-36.
Lasson A, Simren M, Stotzer PO, Isaksson S, Ohman L, Strid H. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis 2013; 19: 576-81.
D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218-24.
Solberg IC, Lygren I, Jahnsen J, Aadland E, Hoie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 431-40.
Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al. The second European evidencebased Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis 2010; 4: 28-62.
Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980; 1: 5.
Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol 2010; 8: 357-6314.
Downloads
How to Cite
Issue
Section
License
Usted es libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y construir a partir del material
- para cualquier propósito, incluso comercialmente.
Bajo los siguientes términos:
-
Atribución — Usted debe dar crédito de manera adecuada, brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
- No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
